Stockscreener 앱 받기
23.97
12.96%
2.75
시장 영업 전:
23.10
-0.87
-3.63%
Assembly Biosciences Inc 주식(ASMB)의 최신 뉴스
Historical volatility pattern of Assembly Biosciences Inc. visualizedYearly Trend Summary and Opportunity Breakdown - Newser
Is a relief rally coming for Assembly Biosciences Inc. holders3-Year Equity Summary With Setup Insights - Newser
Real time breakdown of Assembly Biosciences Inc. stock performanceAnnual Market Behavior and Sector Summary - Newser
Using AI based signals to follow Assembly Biosciences Inc.Swing Trade Watchlist with Entry Zones - Newser
Is Assembly Biosciences Inc. stock poised for growthOversold Reversal Picks with Buy Zone - Newser
Backtesting results for Assembly Biosciences Inc. trading strategiesBuy and Exit Strategy Based on Momentum - Newser
Can you recover from losses in Assembly Biosciences Inc.Free Trend Following Strategy With Stop Loss - Newser
Automated trading signals detected on Assembly Biosciences Inc.Swing Entry Insight With Forecast Accuracy - Newser
Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial - MSN
What the charts say about Assembly Biosciences Inc. todayBreakout Screener With Alert Based Timing - Newser
Assembly Biosciences' ABI-5366 Demonstrates Significant Reductions in HSV-2 Shedding and Genital Lesions - AInvest
Assembly Biosciences' ABI-5366: A Catalyst for Genital Herpes Innovation and Shareholder Value - AInvest
Long term hold vs stop loss in Assembly Biosciences Inc.Real-Time Signal Tracking with Entry Level - Newser
Using fundamentals and technicals on Assembly Biosciences Inc.Risk Aware Swing Trade Analysis Insights - Newser
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts (ASMB) - Seeking Alpha
Assembly Bio touts Phase 1b success in herpes as Gilead buys 2.3M shares - Endpoints News
Assembly Biosciences reports positive data from herpes study - Seeking Alpha
Assembly Biosciences announces pricing of $175M in equity financings - TipRanks
Assembly Biosciences reports interim results from phase 1b study of ABI-5366 - TipRanks
Assembly Biosciences Announces Positive Phase 1b Results - TipRanks
Assembly Bio prices $130 million offering to fund viral disease research - Investing.com India
Assembly Biosciences Announces Pricing of Underwritten Registered Offering and Private Placement - Quiver Quantitative
Assembly Bio reports 94% reduction in HSV-2 shedding with new drug - Investing.com Australia
Assembly Bio reports 94% reduction in HSV-2 shedding with new drug By Investing.com - Investing.com South Africa
Assembly Biosciences raises $109.6M in underwritten, registered offering. - AInvest
Assembly Biosciences Raises $175M in Equity Financing, Gilead Sciences Invests $97M in Private Placement. - AInvest
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - Morningstar
Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 18% last week - simplywall.st
How Resilient Is Assembly Biosciences Inc. Stock During Economic DownturnsBuy/Sell Zone Confirmation Technical Analysis - Newser
What makes Assembly Biosciences Inc. stock price move sharplySummary of Consistent Growth Stock Picks - Newser
How Efficient Is Assembly Biosciences Inc. at Controlling Operating CostsMarket Liquidity and Price Flow Analysis - Newser
Assembly Biosciences 2025 Q2 Earnings Loss Narrows with 32.8% EPS Improvement - AInvest
Assembly Biosciences (ASMB) to Release Earnings on Thursday - Defense World
Assembly Biosciences: Q2 Earnings Snapshot - New Haven Register
Order flow analysis tools used on Assembly Biosciences Inc.Growth Watchlist for Long Term Positioning - Newser
Assembly Biosciences Reports Q2 2025 Progress and Financials - TipRanks
Assembly Biosciences Reports Interim Results for ABI-6250 - TipRanks
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences Reports Positive Phase 1b Results and Milestones for Investigational Viral Therapeutics in Q2 2025 Update - Quiver Quantitative
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - Stock Titan
Is Assembly Biosciences Inc. stock ready for a breakoutRapid Trade Forecast Based on Indicators - Newser
How Assembly Biosciences Inc. stock performs during market volatilityRisk Aware Trading Ideas with Alert Levels - Newser
Assembly Biosciences Inc. Stock Flags Risk Zone in Volatility IndexHigh Win Rate Trading Opportunities Detected - beatles.ru
How many analysts rate Assembly Biosciences Inc. as a “Buy”Free Trading Psychology Coaching - Jammu Links News
Does Assembly Biosciences Inc. stock perform well during market downturnsGet exclusive market analysis for investors - Jammu Links News
What are the latest earnings results for Assembly Biosciences Inc.Market-beating returns - Jammu Links News
Why is Assembly Biosciences Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What are Assembly Biosciences Inc. company’s key revenue driversAchieve breakthrough financial results - Jammu Links News
How does Assembly Biosciences Inc. compare to its industry peersHigh-performance stocks for savvy investors - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):